Form 8-K - Current report:
SEC Accession No. 0001437749-22-028918
Filing Date
2022-12-12
Accepted
2022-12-12 16:30:16
Documents
13
Period of Report
2022-12-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20221212_8k.htm   iXBRL 8-K 32544
  Complete submission text file 0001437749-22-028918.txt   183351

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA navb-20221208.xsd EX-101.SCH 4036
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20221208_def.xml EX-101.DEF 13876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20221208_lab.xml EX-101.LAB 18172
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20221208_pre.xml EX-101.PRE 13898
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20221212_8k_htm.xml XML 4293
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 221457457
SIC: 2835 In Vitro & In Vivo Diagnostic Substances